Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC)

被引：0

作者：

Merle, Philippe

Peron, Jean-Marie

Le Malicot, Karine

Guarssifi, Meriem

Aparicio, Thomas

Bourgeois, Vincent

Assenat, Eric

Blanc, Jean-Frederic

Bouattour, Mohamed

Touchefeu, Yann

Akouz, Faiza Khemissa

Nguyen-Khac, Eric

Bronowicki, Jean-Pierre

Girot, Paul

Lam, You Heng

Bolliet, Marion

Adhoute, Xavier

Edeline, Julien

Nault, Jean-Charles

Phelip, Jean Marc

机构：

[1] Croix Rousse Hosp, Hepatol Unit, Lyon, France

[2] Hop Purpan, Serv Hepatogastroenterol, Toulouse, France

[3] INSERM, U1231, FFCD, Dijon, France

[4] FFCD, Dijon, France

[5] Hop St Louis, AP HP, Dept Gastroenterol, Paris, France

[6] Hop Duchenne, Digest Oncol, Boulogne Sur Mer, France

[7] St Eloi Univ Hosp, Montpellier, France

[8] CHU Bordeaux, Grp Hosp Haut Leveque, Bordeaux, France

[9] Hop Beaujon, AP HP, Clichy, France

[10] CHU Nantes, Dept Hepatogastroenterol, Nantes, France

[11] Hop St Jean, Perpignan, France

[12] CHU Amiens, Amiens, France

[13] Hop Brabois Adulte Nancy, Serv Hepatogastroenterol, Nancy, France

[14] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France

[15] Hop Univ Paris Seine St Denis, Hop Jean Verdier, Bondy, France

[16] Univ Hosp St Etienne, St Priest En Jarez, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16195

引用

页数：1

共 12 条

[11] IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
Breder, Valeriy Vladimirovich
Vogel, Arndt
Merle, Philippe
Finn, Richard S.
Galle, Peter R.
Zhu, Andrew X.
Cheng, Ann-Lii
Feng, Yin-Hsun
Li, Daneng
Gaillard, Vincent E.
Li, Lindong
Nicholas, Alan
Lencioni, Riccardo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[12] TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)
Kudo, Masatoshi
Ueshima, Kazuomi
Ikeda, Masafumi
Torimura, Takuji
Aikata, Hiroshi
Izumi, Namiki
Yamasaki, Takahiro
Hino, Keisuke
Kuzuya, Teiji
Isoda, Norio
Yasui, Kohichiroh
Aino, Hajime
Ido, Akio
Kawabe, Naoto
Nakao, Kazuhiko
Wada, Yoshiyuki
Yoshimura, Kenichi
Okusaka, Takuji
Furuse, Junji
Arai, Yasuaki
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

← 1 2 →